Brief: Transcode Therapeutics Announces FDA Authorization To Proceed With First-In-Human Clinical Trial
Brief: TransCode Therapeutics Announces Withdrawal Of Registration Statement
Brief: Transcode Therapeutics Announces IND Submission To FDA For Advanced Solid Tumors Drug Study
Brief: TransCode Therapeutics Reports Third Quarter 2022 Results, Provides Business Update
Brief: Transcode Therapeutics Reports Positive Preclinical Results With Its Immunotherapy Candidate For Pancreatic Cancer
U.S. STOCKS ON THE MOVE-Moderna, Netflix, Visa
U.S. STOCKS ON THE MOVE-Rollins Inc, Harley-Davidson, Tesla
U.S. STOCKS ON THE MOVE-Alphabet, Boeing, Tesla
TransCode Therapeutics surges on positive trial data for cancer drug
Brief: Transcode Therapeutics Reports Positive Preclinical Results With Its Lead Candidate, Ttx-Mc138, In Pancreatic Adenocarcinoma
Brief: Transcode Therapeutics Appoints Microrna Pioneer, Dr. Frank Slack, To Its Advisory Board
Brief: TransCode Therapeutics Reports Q2 2022 Results
Brief: Transcode Therapeutics And MD Anderson Announce Strategic Alliance To Advance Rna Therapies For Oncology
Brief: Transcode Therapeutics Announces Expansion Of Global RNA Oncology Patent Portfolio
Brief: TransCode Therapeutics Acquires Option for Radiotheranostic Technology
Brief: TransCode Therapeutics Says Cash & Cash Equivalents Sufficient To Fund Planned Operations Into Q1 2023
Brief: TransCode Therapeutics Reports Q3 Loss Per Share $0.20
Brief: Transcode Therapeutics Appoints Zdravka Medarova As Chief Technology Officer
U.S. STOCKS ON THE MOVE-Carnival Corp, Novavax, Dell, energy stocks